drugset / Trial / NCT00002344

A Study of Azithromycin in HIV-Infected Patients

NCT00002344

Phase 1 Completed 12 enrolled Pfizer
Parallel-groupTreatment

Summary

To assess the dose proportionality of azithromycin concentrations and toleration when delivered in tablet formulation to HIV-infected patients. The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule